YOLFTbeta
65

EirGenix Inc.

6589 · TW · Healthcare / Biotechnology

55.60TWD+1.60 (+2.96%)

Price History

Full chart

Market Stats

Previous Close54.00
Open53.90
Day Range52.60 – 56.10
52-Week Range40.15 – 84.30
Volume2.21M
Market Cap15.14B
P/E (TTM)0.00
Forward P/E0.00
EPS-1.86
Dividend Yield0.00%
Beta0.33
50-Day Avg49.42
200-Day Avg52.52

About

EirGenix Inc. operates as a contract development and manufacturing company in Taiwan and internationally. The company offers cell line development, process development, analytical and quality control, cGMP manufacturing mammalian and microbial system, and antibody-drug conjugate services. It is also involved in the development of EG12014/EGI014, a Trastuzumab biosimilar, indicated for the treatment of cancer and currently under biologics license application status; EG1206A, a Pertuzumab biosimilar, indicated for the treatment of cancer and currently under Phase I stage; EG13074, indicated for the treatment of cancer and currently under Preclinical stage; TSY0110(EG12043), an antibody-drug conjugate, indicated for the treatment of cancer and currently under Preclinical stage; EG12021, Bevacizumab biosimilar, indicated for the treatment of cancer and currently under Preclinical stage; and EG62054, a biosimilar, currently under Preclinical stage. In addition, the company manufactures and sells covid-19 antigen rapid test; and EG74032, a CRM197 carrier protein. The company was incorporated in 2012 and is headquartered in New Taipei City, Taiwan.

Company Details

  • SectorHealthcare
  • IndustryBiotechnology
  • CEODr. Lee-Cheng Liu
  • HeadquartersNo. 101, Kangning Street, New Taipei City, Taiwan, Taiwan
  • Websitehttps://www.eirgenix.com

Leadership

  • Dr. Lee-Cheng LiuFounder, President, CEO, CSO & Chairman
  • Ms. Hsiu-Chuan YangCFO, VP & Manager of Corporate Governance
  • Dr. Chih-Jung ChangSenior VP, CEO of BMBU
  • Dr. Shang-Chung JuExecutive Director & Chief Engineer
  • Ms. Ching-Ying ChenExecutive Director
  • Xiuquan YangAccounting Supervisor
  • Dr. Ching-Wen Lin B.S, M.S, Ph.D.Senior VP & Chief Business Officer
  • Dr. Klaus Martin Ph.D.Senior VP & CEO of Biopharmaceuticals Business Unit

Financials

Income Statement

Currency: TWD2021-12-312022-12-312023-12-312024-12-312025-12-31
Total Revenue1.70B1.48B1.02B1.01B1.01B
Growth (%)--12.75%-30.95%-1.34%-0.38%
Cost of Revenue604.30M724.57M785.91M789.98M811.33M
Gross Profit1.09B756.45M236.74M218.99M193.83M
Gross Margin64.40%51.08%23.15%21.70%19.28%
Operating Expense1.15B1.09B1.27B1.08B1.04B
Operating Income-57.62M-331.21M-1.03B-865.87M-843.38M
Operating Margin-3.39%-22.36%-100.91%-85.82%-83.90%
EBITDA-100.61M-664.41M-388.50M-505.46M
EBITDA Margin-6.79%-64.97%-38.51%-50.29%
Net Income-42.58M-115.54M-915.21M-698.34M-760.55M
Net Income Margin-2.51%-7.80%-89.49%-69.21%-75.67%
R&D893.51M800.14M952.29M785.88M702.35M
R&D as % of Total Revenue52.64%54.03%93.12%77.89%69.87%
Interest Expense21.15M9.64M10.40M6.43M8.22M
Interest Expense % of Total Revenue1.25%0.65%1.02%0.64%0.82%

Balance Sheet

Currency: TWD2021-12-312022-12-312023-12-312024-12-312025-12-31
Total Assets11.44B11.85B11.16B10.88B10.95B
Total Liabilities1.01B1.16B1.15B1.62B2.61B
Total Equity10.43B10.68B10.02B9.26B8.34B
Cash6.63B6.13B5.05B4.10B3.53B

Cash Flow

Currency: TWD2021-12-312022-12-312023-12-312024-12-312025-12-31
Operating Cash Flow-29.90M-147.52M-848.56M-311.44M298.01M
Capital Expenditure169.71M788.40M728.87M927.64M1.62B
Free Cash Flow-199.61M-935.91M-1.58B-1.24B-1.32B
FCF to OCF667.61%634.44%185.89%397.85%-444.21%

Earnings

Report DateAug 14, 2019Nov 13, 2019May 14, 2020Aug 14, 2020Nov 13, 2020Mar 26, 2021Aug 13, 2021Nov 11, 2021May 13, 2022Aug 12, 2022Nov 10, 2022May 15, 2023Aug 9, 2023Nov 13, 2023Mar 22, 2024Aug 14, 2024Nov 13, 2024Mar 14, 2025Mar 31, 2025Aug 14, 2025Nov 13, 2025Aug 14, 2026
EPS Estimate-0.82-0.83-1.87-1.44-1.10-0.95-0.910.390.620.19-0.30-0.270.01-0.49-0.13-0.70-0.86-0.71-0.56-0.52-0.60-0.70
EPS Actual-0.87-1.78-2.06-1.74-0.34-1.44-0.651.340.050.02-0.09-0.67-0.64-0.37-1.33-0.72-0.84-0.38-0.52-1.23-0.20-0.64
Surprise-6.10%-114.46%-10.16%-20.83%69.09%-51.58%28.57%243.59%-91.94%-89.47%70.00%-148.15%-6500.00%24.49%-923.08%-2.86%2.33%46.48%7.14%-136.54%66.67%8.57%
TimingPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketAfter-hoursAfter-hoursPre-marketPre-marketAfter-hoursPre-marketAfter-hoursAfter-hoursPre-marketPre-marketPre-marketPre-market-Pre-marketAfter-hoursPre-market

Key Statistics & Ratios

Market Cap15.14B
Enterprise Value14.97B
Trailing P/E0.00
Forward P/E0.00
Price / Sales12.48
Price / Book2.06
EPS-1.86
Book Value26.09
Revenue (TTM)1.21B
Gross Profit (TTM)361.09M
EBITDA-631.83M
Profit Margin-46.89%
Operating Margin-64.72%
Return on Equity-7.00%
Return on Assets-5.10%
Shares Outstanding298.07M
Shares Float188.83M
Beta0.33
Dividend Yield0.00%
Dividend Rate0.00
Payout Ratio0.00%